DNLI: the cashflow

MyFinsight

For the quarter ending 2025-09-30, DNLI had -$50,244K decrease in cash & cash equivalents over the period. -$105,918K in free cash flow.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Net loss	-126,902	-257,089
Depreciation and amortization	2,947	5,370
Stockbased compensation expense	25,135	50,547
Net accretion of discounts on marketable securities	2,026	6,585
Non-cash adjustment to operating lease expense	1,144	2,161
Right-of-use asset amortization for finance lease	915	1,798
Non-cash gain from divestiture of small molecule programs	0	0
Prepaid expenses and other current assets	-1,363	3,650
Other non-current assets	1,717	-3,022
Accounts payable	-4,069	-43
Accruals and other current liabilities	1,889	-14,151
Deferred research and development funding liability	-3,687	16,176
Net cash used in operating activities	-107,296	-206,766
Purchases of marketable securities	50,629	137,926
Maturities and sales of marketable securities	107,081	323,965
Purchases of property and equipment	-1,378	9,356
Net cash provided by (used in) investing activities	57,830	176,683
Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs of 480	0	0
Proceeds from exercise of awards under equity incentive plans	583	4,652
Payments for finance lease right-of-use asset	1,361	6,791
Net cash (used in) provided by financing activities	-778	-2,139
Net decrease in cash, cash equivalents and restricted cash	-50,244	-32,222
Cash and cash equivalents at beginning of period	176,535	-
Cash and cash equivalents at end of period	94,069	-

Unit: Thousand (K) dollars